Zimmer Biomet Announces Fourth Quarter and Full-Year 2022 Financial Results

Fourth quarter net sales from continuing operations of $1.825 billion increased 2.7% and 8.3% on a constant currency1 basis Fourth quarter diluted loss per...

Related Keywords

United States ,Switzerland ,Warsaw ,L67 ,Poland ,Swiss ,Bryan Hanson ,Zimmer Biomet ,Meredith Weissman ,Keri Mattox ,Heather Zoumas Lubeski ,Holdings Inc ,Prnewswire Zimmer Biomet Holdings Inc ,Organisation For Economic ,Union Medical Device Regulation ,Zimmer Biomet Osseoti Porous Metal Technology ,Drug Administration ,Foreign Currency Exchange Impact ,Zimvie Inc ,Exchange Commission ,Net Loss Of Zimmer Biomet Holdings Inc ,Net Earnings Of Zimmer Biomet Holdings Inc ,Zimmer Biomet Holdings Inc ,European Union Medical Device Regulation ,Operations Of Zimmer Biomet Holdings Inc ,Biomet Holdings ,Keel Tibia ,Persona Knee System ,Osseoti Porous Metal Technology ,Apple Watch ,Product Category ,Sports Medicine ,Year Ending December ,Investor Relations ,Private Securities Litigation Reform Act ,Economic Co Operation ,Warsaw North Campus ,Annual Report ,Note Regarding Forward Looking ,Continuing Operations ,Zimmer Biomet Holdings ,Per Common Share ,Loss Per Common Share ,Earnings Per Common Share ,Three Months ,Warning Letter ,Adjusted Diluted ,Months Ended December ,Ended December ,Medical Device Regulation ,Nc ,